Corcept TherapeuticsFRA:HTD +6.82%90 PB Ratio is 14.75 as of Jun. 27, 2026, which is 142% above its 10-year median of 6.09. GuruFocus rates FRA:HTD with a GF Score™ of 90/100 and a GF Value™ of €53.55 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 1,232 Biotechnology companies, Corcept Therapeutics ranks worse than 91.15% on this metric.
Corcept Therapeutics Inc stock PB Ratio (=14.69) is close to 5-year high of 14.69.
The historical rank and industry rank for Corcept Therapeutics's PB Ratio or its related term are showing as below:
FRA:HTD'
s PB Ratio Range Over the Past 10 Years
Min: 3.17 Med: 6.09 Max: 34.47
Current: 14.69
During the past 13 years, Corcept Therapeutics's highest PB Ratio was 34.47. The lowest was 3.17. And the median was 6.09.
FRA:HTD's PB Ratio is ranked worse than 91.15% of 1232
companies
in the Biotechnology industry
Industry Median: 2.8
vs FRA:HTD: 14.69
During the past 12 months, Corcept Therapeutics's average Book Value Per Share Growth Rate was -7.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 9.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 10.20% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 36.30% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Corcept Therapeutics was 142.10% per year. The lowest was -43.10% per year. And the median was 12.70% per year.
Back to Basics: PB Ratio
Corcept Therapeutics (FRA:HTD) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Corcept Therapeutics PB Ratio Related Terms
Corcept Therapeutics PB Ratio Historical Data
* Premium members only.
The historical data trend for Corcept Therapeutics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Corcept Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corcept Therapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Corcept Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Corcept Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Corcept Therapeutics (FRA:HTD) has a PB Ratio of 14.75 as of Jun. 27, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Corcept Therapeutics and its competitors. This is 142% above median its historical median of 6.09. Over the past decade, Corcept Therapeutics' PB Ratio has ranged from 3.17 to 34.47. According to the industry distribution chart, Corcept Therapeutics ranks #1123 out of 1232 companies in the Biotechnology industry, placing it in the top 91.2%.
Is Corcept Therapeutics' PB Ratio too high?
Corcept Therapeutics' current PB Ratio of 14.75 is 142% above median its 10-year median of 6.09. Over the past 10 years, this metric has ranged from a low of 3.17 to a high of 34.47. The Biotechnology industry median PB Ratio is 2.80. Corcept Therapeutics' value of 14.75 is 426.8% above this industry median. Based on the distribution chart, Corcept Therapeutics ranks #1123 out of 1232 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Corcept Therapeutics has a GF Score™ of 90/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Corcept Therapeutics' PB Ratio compare to PCVX and IBRX?
According to the Biotechnology industry distribution chart, Corcept Therapeutics ranks #1123 out of 1232 companies for PB Ratio. This places Corcept Therapeutics in the lower half of its industry. The industry median PB Ratio is 2.80. Corcept Therapeutics' value of 14.75 is 426.8% above this benchmark. Historically, Corcept Therapeutics' own PB Ratio has ranged from 3.17 to 34.47 over the past decade. While the company's 10-year median is 6.09 vs. the industry median of 2.80, Corcept Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Corcept Therapeutics's current PB Ratio of 14.75 is 426.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Corcept Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Corcept Therapeutics's current PB Ratio is 14.75, which is 142% above median its own 10-year median of 6.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corcept Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Corcept Therapeutics (FRA:HTD) is currently considered Significantly Overvalued. The stock's GF Value™ is €53.55, compared to a current price of €75.82 — trading 41.6% above its estimated fair value. The current PB Ratio is 14.75, which is 142% above median its 10-year median of 6.09 and 426.8% above the Biotechnology industry median of 2.80. Corcept Therapeutics' overall GF Score™ is 90/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Corcept Therapeutics (FRA:HTD), the current PB Ratio is 14.75 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Corcept Therapeutics (FRA:HTD) Overvalued in 2026?
Based on GuruFocus' analysis, Corcept Therapeutics stock appears to be overvalued.
The current stock price of €75.82 is trading 41.6% above its estimated GF Value™ of €53.55.
GuruFocus considers Corcept Therapeutics to be Significantly Overvalued.
Key valuation signals for FRA:HTD:
PB Ratio: 14.75 (142% above median its 10-year median of 6.09)
GF Value™: €53.55 vs. price of €75.82 (41.6% above fair value)
Industry Position: 426.8% above the Biotechnology median (#1123 of 1232)
No single metric tells the full story. See the FRA:HTD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
90GF Score
Get the complete analysis for FRA:HTD
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:HTD has been successfully added to your 
